PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma
Publication in refereed journal

香港中文大學研究人員

引用次數
替代計量分析
.

其它資訊
摘要Purpose PR-104 is activated by reductases under hypoxia or by aldo-keto reductase 1C3 (AKR1C3) to form cytotoxic nitrogen mustards. Hepatocellular carcinoma (HCC) displays extensive hypoxia and expresses AKR1C3. This study evaluated the safety and efficacy of PR-104 plus sorafenib in HCC.
著者Abou-Alfa GK, Chan SL, Lin CC, Chiorean EG, Holcombe RF, Mulcahy MF, Carter WD, Patel K, Wilson WR, Melink TJ, Gutheil JC, Tsao CJ
期刊名稱Cancer Chemotherapy and Pharmacology
詳細描述[Epub ahead of print].
出版年份2011
月份8
日期1
卷號68
期次2
出版社SPRINGER
頁次539 - 545
國際標準期刊號0344-5704
電子國際標準期刊號1432-0843
語言英式英語
關鍵詞AKR1C3; Hepatocellular carcinoma; PR-104; Sorafenib
Web of Science 學科類別Oncology; ONCOLOGY; Pharmacology & Pharmacy; PHARMACOLOGY & PHARMACY

上次更新時間 2020-30-11 於 00:06